Upgrade to SI Premium - Free Trial

Valeant (VRX) Divestitures 'Unlikely' Near-Term, Says Rodman & Renshaw

April 11, 2016 8:21 AM
Rodman & Renshaw reiterated a Buy rating on Valeant Pharmaceuticals (NYSE: VRX) with an updated price target of $105.00 (prior ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change Rumors

Next Articles